Last updated: March 11, 2024
Sponsor: Laureate Institute for Brain Research, Inc.
Overall Status: Active - Recruiting
Phase
1/2
Condition
Bipolar Disorder
Depression
Depression (Treatment-resistant)
Treatment
Exercise Session
Ibuprofen 800 mg
Rest
Clinical Study ID
NCT06088732
2023-001
Ages 18-55 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Has an established residence and phone
- Agrees to and is eligible for behavioral testing, magnetic resonance imaging, andblood draws.
- Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of thestudy
- Males and females; Age 18-55 years
- DSM-V diagnosis of bipolar disorder
- Has a current major depressive episode
- Depression at enrollment of sufficient severity to score > 11 on the QIDS
- Be stably medicated for at least 4 weeks (a non-medicated subject may be included inthe study if judged to be appropriate in the medical/psychiatric opinion of theinvestigator)
- BMI between 18.5 and 35
Exclusion
Exclusion Criteria:
- Diagnosis of any other major psychiatric disorder such as schizoaffective disorder,schizophrenia, or current psychotic depression
- A history of bipolar disorder with rapid cycling
- Concurrent manic symptoms of sufficient severity to pose a substantial risk of thedevelopment of a manic episode (>19 on the YMRS)
- Current drug or alcohol or substance use disorder moderate or severe, except nicotine (within 6 months for severe use disorder; 2 months for moderate use disorder)
- Volunteers currently receiving more than 4 mood-relevant psychotropic medications in adaily regimen (since this may signify a more brittle or complex clinical state)
- Taking any of the following medications: medications with significant interactionswith ibuprofen; immune-modulating medications (e.g. oral steroids); regular use ofNSAIDs (> 3 times per week)
- Current or prior cardiac disease, cardiac arrhythmia (e.g. supraventriculartachycardia, atrial fibrillation, ventricular fibrillation), or history of cardiacablation therapy
- Unstable medical condition, including significant respiratory disease (e.g., asthma,reactive airway disease (i.e., exercise induced asthma), or chronic obstructivepulmonary disease (COPD)), liver disease, hypothyroidism (i.e., condition notadequately stabilized for 3 months), or other conditions likely to requirehospitalization or with a life expectancy of < 6 months (e.g., cancer).
- History of claustrophobia that would prevent participation in imaging scans
- Actively suicidal, as defined by expressive ideation with a plan and intent forsuicide or developing suicidal ideation that requires immediate medical or treatmentintervention or a suicide attempt within the previous six months
- Participants who endorse a history of moderate to severe traumatic brain injury (>30min. loss of consciousness or >24 hours posttraumatic amnesia) or other neurocognitivedisorder with evidence of neurological deficits
- Inadequate understanding of English
- Currently pregnant or breast-feeding; fecund women not using adequate contraceptivemethods; plan to become pregnant within 12 months
- Metal in the body (e.g. history of working as a sheet metal worker) or pacemaker whichis a contra-indication to magnetic resonance imaging
- Has epilepsy, a neuromuscular disorder, or tardive dyskinesia
- Has a chronic infectious illness
- Requires immediate hospitalization for psychiatric disorder
- Requires medications for a general medical condition that contraindicate any studymedication
- Receiving or have received during the index episode vagus nerve stimulation,electroconvulsive therapy, transcranial magnetic stimulation, or other somatictreatments
- Allergy to, or other medical contraindication to ibuprofen (e.g. stomach ulcers)
- Symptoms of myalgic encephalomyelitis/chronic fatigue syndrome or "long-COVID".
- Current use of medications or dietary supplements for weight or appetite control,whether prescribed or not
- Ulcerative colitis, Crohn's disease or other autoimmune disorder (except treatedhypothyroidism)
- Activity restrictions that limit the subject's ability to engage in intense physicalactivity
- Use of beta-blockers, calcium channel inhibitors, or other heart-modulatingmedications (e.g., amiodarone)
- Clinically significant abnormality on EKG
- Hypertension, hepatitis, renal dysfunction, and/or anemia of sufficient severity topose a risk to the participant
- Moderate or heavy smoker based on Fagerstrom
- Resting heart rate >100 beats per minute, systolic blood pressure > 160 mmHg,diastolic blood pressure > 100 mmHg
- Clinically significant screening laboratory abnormalities not covered above
- Any reason not listed herein that would make participation in the study hazardous
Study Design
Total Participants: 20
Treatment Group(s): 4
Primary Treatment: Exercise Session
Phase: 1/2
Study Start date:
March 12, 2024
Estimated Completion Date:
December 31, 2026
Connect with a study center
Laureate Institute for Brain Research
Tulsa, Oklahoma 74136
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.